News for ACADIA Pharmaceuticals Inc. (ACAD)

UBS has revised its price target for Acadia Pharmaceuticals (ACAD) to $22, down from $25, while maintaining a Buy rating. The estimate adjustment follows Acadia

Summary ACADIA Pharmaceuticals Inc (ACAD) has announced that it will release its first quarter financial results on Wednesday, May 7, 2025, following the closur

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of th

Bank of America has revised its price target for Acadia Pharmaceuticals (ACAD), reducing it slightly from $19 to $18. Despite this adjustment, the bank maintain

Summary ACADIA Pharmaceuticals Inc (ACAD) announced on April 3, 2025, that its Compensation Committee has granted inducement awards to twenty-two new employees

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 3, 2025, the Compensation Committee of Acadia's Board of Directors (the ”œCommittee”

Acadia Pharmaceuticals (ACAD) granted inducement awards to 22 new employees under its 2024 Inducement Plan. The awards include stock options for 172,637

**media[579898]**

On March 17, 2025, Baker Bros. Advisors LP executed a significant transaction involving Immunocore Holdings PLC. The firm added 807,338 shares to its holdings,

[url=

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 5, 2025, the Compensation Committee of Acadia's Board of Directors (the ”œCommittee”

The Nasdaq has had a challenging start to 2025, with the index dropping nearly 12% YTD, as of March 13.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences: UBS Virtual CNS Day 2025 Fi

On March 5, 2025, Elizabeth Garofalo, Director at ACADIA Pharmaceuticals Inc (ACAD), sold 4,919 shares of the company, according to a SEC Filing. Following this

Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

ACADIA Pharmaceuticals Inc (ACAD) and Saniona have announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending

Acadia is seeing solid growth from its two products on the market. Check out the analysis of ACAD stock following Q4 numbers and FY2025 initial guidance.

On February 28, 2025, Baker Bros. Advisors LP executed a significant transaction involving BeOne Medicines Ltd (ONC). The firm reduced its holdings by 470,215 s

Total Revenue (Q4 2024): $259.6 million, up 12% year over year.Total Revenue (Full Year 2024): $957.8 million, up 32% from the prior year.DAYBUE Sales (Q4 2024